Tidepath

More GLP-1 drugs

Dulaglutide

Also called Trulicity

A once-a-week GLP-1 shot, built by joining a GLP-1-like chain to part of an antibody1.

Status
Approved by the FDA in 2014 for type 2 diabetes, as Trulicity4.
How it's taken
By injection

What it is

Trulicity is dulaglutide, a GLP-1 drug1. GLP-1 is a hormone your gut releases when you eat2. Dulaglutide acts on the same receptor: it raises insulin when blood sugar is high, lowers glucagon (a hormone that raises blood sugar), and slows how fast the stomach empties1. Natural GLP-1 lasts only minutes in the body3. Dulaglutide is an engineered protein built to last much longer3. Its half-life, the time it takes for half a dose to clear, is about 5 days1. Trulicity is approved to improve blood sugar, alongside diet and exercise, in adults and children 10 and older with type 2 diabetes1. It's also approved to lower the risk of major heart events (a heart attack, a stroke, or death from heart or blood vessel disease) in adults with type 2 diabetes who have heart or blood vessel disease or several risk factors for it1.

What makes it distinct

Dulaglutide is a fusion protein: a GLP-1-like chain joined to a piece of a modified human antibody (the Fc part of an antibody type called IgG4), with two of these identical chains linked together1. Its developers built it to last longer than natural GLP-1, and their early animal studies supported testing it as a once-a-week treatment3.

What the evidence shows

Trulicity was studied in adults with type 2 diabetes, on its own and added to other diabetes medicines, including insulin1. Its trials compared it with placebo, a dummy treatment, and with other diabetes medicines, measuring HbA1c, a blood test of average blood sugar over the past few months1. Against placebo, HbA1c fell more on Trulicity1. It was also studied in adults with type 2 diabetes and moderate to severe kidney disease, and in children 10 and older1. REWIND, a heart-outcomes trial, followed 9,901 adults aged 50 and over with type 2 diabetes for a median (the middle value) of 5.4 years15. Each had either had a previous heart or blood vessel event or had risk factors for one5. Fewer people had a major heart event on dulaglutide than on placebo5. Deaths from any cause did not differ between the groups, and digestive side effects were reported more often on dulaglutide5.

Open questions

  • Whether it causes thyroid tumors in people. In animal studies it caused thyroid C-cell tumors (C-cells are a type of cell in the thyroid), and its label says it isn't known whether that happens in people1.
  • What antibodies the body makes against the drug (anti-drug antibodies) mean for children. They were too rare in the children's trial for their effect to be known1.

Worth knowing

Trulicity's approved uses are blood sugar control and lowering heart risk in type 2 diabetes; weight management isn't one of them1.

Sources

  1. TRULICITY (dulaglutide) injection, prescribing information, Eli Lilly (DailyMed; label effective June 2026)
  2. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
  3. Glaesner W et al. Engineering and characterization of the long-acting GLP-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010 (PubMed 20503261)
  4. Drugs@FDA: BLA 125469, TRULICITY (dulaglutide)
  5. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019 (PubMed 31189511)

More in More GLP-1 drugs